Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Organogenesis Holdings Inc.NASDAQ: ORGO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $12.37M rose 96.9% year over year, ahead of the +45.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 76.4% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.

Context

  • Depreciation & amortization amounted to 4.8% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +96.9% holds above the trailing-twelve-month pace of +45.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.37M+76.4% QoQ
Last fiscal yearDec 2025
$26.94M+58.2% YoY
LTMMar 2026
$30.95M+45.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.9%——
1 year+58.2%——
3-year CAGR+35.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
26.94M USD
Year-over-year change
+58.2%
4-year CAGR
+12.7%

Depreciation & Amortization vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.2% is the 3rd highest of 10, against a peer median of -0.7%.
  • Depreciation & amortization amounts to 6.0% of revenue for ORGO, versus a peer median of 3.2%.
ORGO Competitors
Depreciation & Amortization for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$93.9M USD-11.7%-12.6%13.9%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$30.95M USD+45.2%+35.9%6.0%
VREXVarex Imaging CorporationLTM Apr 2026$27.1M USD-0.7%-6.8%3.2%
ANGOAngioDynamics, Inc.LTM Feb 2026$23.19M USD-13.4%-4.2%7.4%
EOLSEvolus, Inc.LTM Mar 2026$9.61M USD+52.7%+24.8%3.2%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$1.5M USD+328.5%-40.6%0.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$577.25K USD+7.8%+2.8%0.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$511.27K USD-107.2%+20.3%0.8%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$468K USD-128.3%——
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding ORGO) —-0.7%-0.7%3.2%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income94.9M15.53M4.95M861K37.03M
Depreciation & Amortization16.68M10.73M23.45M17.03M26.94M
Deferred Income Tax(31.98M)1.98M2.01M(10.72M)9.5M
Stock-Based Compensation3.86M6.55M9M10.58M13.3M
Change in Working Capital(39.29M)(34.08M)(18.07M)(48.89M)(132.38M)
Accounts Receivables(30.23M)(8.77M)5.54M(31.8M)(115.8M)
Inventory(9.3M)(9.41M)6.58M(6.2M)(17.92M)
Accounts Payables3.85M3.26M(108K)(2.37M)(528K)
Other Working Capital(3.6M)(19.16M)(30.08M)(8.51M)1.87M
Other Non-Cash Items17.8M24.15M9.59M45.35M35.3M
Operating Cash Flow61.98M24.86M30.92M14.21M(10.31M)
Capital Expenditures(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Debt Repayment(2.01M)(3.01M)(5.17M)(67.64M)(1.17M)
Common Stock Issued2.2M000157K
Common Stock Repurchased000(25.48M)0
Dividends Paid000(1.8M)0
Other Financing Activities(1.22M)814K(332K)1.87M(16.35M)
Financing Cash Flow(1.04M)(2.2M)(5.51M)27.64M(17.36M)
Effect of Forex Changes00000
Net Change in Cash29.72M(11.24M)1.05M31.81M(41.82M)
Free Cash Flow30.76M(9.04M)6.55M4.18M(24.46M)

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.